Cholinergic Urticaria
7
0
0
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
14.3%
1 terminated out of 7 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
Identification of Subpopulations of Patients With Cholinergic Urticaria Based on Infrared Exposure Test Results.
Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria
Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria
Assessment of Serum Levels of Janus Kinase 1 and 2 in Patients With Cholinergic Urticaria
Cholinergic Urticaria - Efficacy of Dupilumab
A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria
Efficacy Study of Omalizumab in Cholinergic Urticaria